Oxcarbazepine Tablet, Film Coated
Product Images NDC 70518-2276

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 70518-2276). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Label for OXcarbazepine 300 mg film-coated tablets, quantity 30, repackaged by RemedyRepack Inc., Indiana, PA. The label includes the NDC number 70518-2276-00, manufacturer Breckenridge in Boca Raton, FL, and storage instructions with temperature ranges. The label also contains a QR code and a caution to keep medication out of children's reach.*

FDA Label Image

Chemical Structure (Oxcarbazepine 01)

Chemical structure of oxcarbazepine, showing its molecular configuration including two benzene rings attached to a central heterocyclic ring with an amide group (CONH2) and a ketone (O) functional group.*

FDA Label Image

Figure 1 (Oxcarbazepine 02)

A Kaplan-Meier curve chart showing exit rate over time on trial from Day 2 to Day 11. The chart compares two treatment groups: Oxcarbazepine (solid line) and Placebo (dotted line). The exit rate is plotted on the y-axis, and days on the x-axis. A log-rank test p-value of 0.0001 is displayed.*

FDA Label Image

Figure 2 (Oxcarbazepine 03)

A survival curve chart showing seizure rates over days from first dose to first seizure, comparing two treatment groups: Oxcarbazepine and Placebo. The y-axis represents seizure rate from 0.0 to 1.0, and the x-axis shows days from 0 to 140. Oxcarbazepine group is shown with a solid line, and placebo with a dotted line. A log-rank test p-value of 0.046 is displayed on the chart.*

FDA Label Image

Figure 3 (Oxcarbazepine 04)

A line chart depicting exit rates over time in days, comparing two treatment groups labeled HIGH (solid line) and LOW (dotted line). The exit rate increases more rapidly for the LOW group within 50 days. A log-rank test p-value of 0.0001 is noted, indicating statistical significance between the groups.*

FDA Label Image

Figure 4 (Oxcarbazepine 05)

A Kaplan-Meier curve displaying exit rates over time for Oxcarbazepine treatment groups. The x-axis represents time to exit in days, up to 130 days, and the y-axis shows the exit rate from 0 to 1. Two treatment groups are shown: HIGH (solid line) and LOW (dotted line). The LOW group has a notably higher exit rate over time. A log-rank test with a p-value of 0.0001 is indicated, demonstrating a statistically significant difference between the groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.